Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 14;7(3):e1056. doi: 10.1038/tp.2017.10

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Patient flow in each treatment groups throughout the study. The enrolled and the included patients are noted followed by the four groups who received 0.5, 1.0 and 2 mg twice daily or placebo. Then the number of patients discontinuing the trial because of an adverse event (AE) or loss to follow-up is indicated, followed by the number of patients who completed the trial for each subgroup. One of the three discontinued patients in the placebo group withdrew after the visit on day 90 and was considered as a completer.